Showing 2381-2390 of 5623 results for "".
- NIH Researchers Develop First Stem Cell Model of Albinism to Study Related Eye Conditionshttps://modernod.com/news/nih-researchers-develop-first-stem-cell-model-of-albinism-to-study-related-eye-conditions/2480560/Researchers at the National Eye Institute (NEI) have developed the first patient-derived stem cell model for studying eye conditions related to oculocutaneous albinism (OCA). The model’s development is described in the January issue of the journal Stem Cell
- CooperVision Facilitates Special Olympics “Opening Eyes” CE Serieshttps://modernod.com/news/coopervision-facilitates-special-olympics-opening-eyes-ce-series/2480559/As part of its ongoing partnership with the Special Olympics Lions Clubs International Foundation Opening Eyes program, CooperVision is helping to facilitate a new continuing education series for eye care professionals (ECPs). The coursework explores ocular and general health concerns for pe
- Regenxbio Announces Initiation of Second Pivotal Trial in RGX-314 Clinical Program for the Treatment of Wet AMD Using Subretinal Deliveryhttps://modernod.com/news/regenxbio-announces-initiation-of-second-pivotal-trial-in-rgx-314-clinical-program-for-the-treatment-of-wet-amd-using-subretinal-delivery/2480556/Regenxbio announced the initiation of ASCENT, the second of two phase 3 pivotal trials to evaluate the efficacy and safety of subretinal delivery of RGX-314 in patients with wet age-related macular degeneration (AMD). ASCENT, the first trial to be initiated by Regenxbio under the e
- Gentex Announces Partnership With eSight To Develop Next Generation Digital Eyewearhttps://modernod.com/news/gentex-announces-partnership-with-esight-to-develop-next-generation-digital-eyewear/2480538/Gentex announced that it is partnering with eSight, provider of vision enhancement technology, to develop and manufacture the next generation of mobile electronic eyewear designed to help people living with visual impairments. Terms of the d
- Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 Trial in Glaucomahttps://modernod.com/news/nicox-announces-first-patient-in-china-screened-in-the-ongoing-ncx-470-denali-phase-3-trial-in-glaucoma/2480521/Nicox SA announced that the first patient has been screened in China in the ongoing Denali phase 3 clinical trial, opening the way for new drug application (NDA) submissions in both the United States and China for NCX 470, Nicox’s lead clinical product candidate in glaucoma. Denali, wh
- Mitotech Granted Orphan Drug Designation by FDA for Visomitin in LHONhttps://modernod.com/news/mitotech-granted-orphan-drug-designation-by-fda-for-visomitin-in-lhon/2480520/Luxembourg-based Mitotech SA announced that the FDA has granted orphan drug designation (ODD) for the company’s topical cardiolipin peroxidation inhibitor, Visomitin, for the treatment of Leber’s Hereditary Optic Neuropathy (LHON), a rare inherited condition that can lead to blin
- GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral Lumevoq Injections at 2-Year Follow-Up of REFLECT Phase 3 Trialhttps://modernod.com/news/gensight-biologics-confirms-sustained-efficacy-and-safety-of-bilateral-lumevoq-injections-at-2-year-follow-up-of-reflect-phase-3-trial/2480513/GenSight Biologics reported topline efficacy and safety results at 2 years post-treatment administration in the REFLECT Phase 3 clinical trial with Lumevoq. The results show sustained efficacy and safety for bilateral intravitreal injection of the gene therapy, including better efficacy compared
- NIH Study Traces Molecular Link From Gene to Late-Onset Retinal Degenerationhttps://modernod.com/news/nih-study-traces-molecular-link-from-gene-to-late-onset-retinal-degeneration/2480510/Scientists have discovered that gene therapy and the diabetes drug metformin may be potential treatments for late-onset retinal degeneration (L-ORD), a rare, blinding eye disease. Researchers from the National Eye Institute (NEI), part of the National Institutes of Health, generated a “dise
- Nicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and Nonclinical Developmenthttps://modernod.com/news/nicox-appoints-doug-hubatsch-as-new-chief-scientific-officer-to-lead-clinical-and-nonclinical-development/2480509/Nicox SA announced the appointment of Doug Hubatsch to lead all of the company’s nonclinical and clinical development activities. As Chief Scientific Officer, Mr. Hubatsch will be responsible for setting the research and development st
- Novartis Announces Positive Year 2 Results of Phase 3 KESTREL Study of Beovu in Diabetic Macular Edemahttps://modernod.com/news/novartis-announces-positive-results-from-year-2-of-the-phase-3-trial-of-beovu-in-diabetic-macular-edema/2480504/Novartis announced the first interpretable results from year 2 (week 100) of the phase 3 KESTREL study. KESTREL assessed the safety and efficacy of Beovu (brolucizumab) 6 mg in patients with visual impairment due to diabetic macular edema (DME). Results from year 2 confirmed the visual acuit